Stockscreener 앱 받기
109.27
1.28%
1.38
시장 영업 전:
110.05
0.78
+0.71%
전일 마감가:
$107.89
열려 있는:
$107.99
하루 거래량:
7.28M
Relative Volume:
0.96
시가총액:
$132.93B
수익:
$28.75B
순이익/손실:
$480.00M
주가수익비율:
295.32
EPS:
0.37
순현금흐름:
$10.31B
1주 성능:
+1.64%
1개월 성능:
-1.08%
6개월 성능:
+31.59%
1년 성능:
+50.90%
1일 변동 폭
$107.90
$110.46
1주일 범위
$104.70
$110.46
52주 변동 폭
$62.07
$119.96
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
GILD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
109.27 | 132.93B | 28.75B | 480.00M | 10.31B | 0.37 |
|
LLY
Lilly Eli Co
|
826.76 | 742.57B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
201.30 | 356.10B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
161.72 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
71.73 | 334.39B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
MRK
Merck Co Inc
|
88.11 | 235.20B | 64.17B | 17.12B | 18.10B | 6.73 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-04 | 재확인 | Oppenheimer | Outperform |
| 2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
| 2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 재확인 | Maxim Group | Buy |
| 2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Reduce |
| 2023-07-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 재개 | Piper Sandler | Overweight |
| 2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 재개 | BofA Securities | Neutral |
| 2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
| 2022-10-28 | 재확인 | Cowen | Outperform |
| 2022-10-28 | 재확인 | JP Morgan | Overweight |
| 2022-10-28 | 재확인 | Jefferies | Buy |
| 2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-10-28 | 업그레이드 | Truist | Hold → Buy |
| 2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
| 2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-02 | 재확인 | BofA Securities | Neutral |
| 2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-02-02 | 재확인 | Truist | Hold |
| 2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Argus | Hold → Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 재개 | Piper Sandler | Neutral |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
| 2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
| 2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-09-30 | 재개 | Jefferies | Buy |
| 2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-31 | 재확인 | Credit Suisse | Neutral |
| 2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 재확인 | Piper Sandler | Overweight |
| 2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
| 2020-07-31 | 재확인 | SunTrust | Hold |
| 2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
| 2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
| 2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
| 2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
JPMorgan Adjusts Price Target on Gilead Sciences to $130 From $120, Maintains Overweight Rating - Marketscreener.com
Potential federal budget cuts won't rock Gilead's HIV boat too much: analysts - FiercePharma
Gilead’s HIV Treatments Could Face Headwinds. Why the Stock Will Still Rise. - Barron's
Are Medical Stocks Lagging Gilead Sciences (GILD) This Year? - Yahoo Finance
Gilead price tries to regain footingForecast today26-03-2025 - Economies.com
Former Gilead Sciences VP Named CEO as Biomea Advances Breakthrough Diabetes Drug - StockTitan
Gilead, J&J Sue Laurus Labs to Block Copy of HIV Drug Complera - Bloomberg Law
Gilead Sciences: Using Lessons From the HIV Epidemic To Help Reduce Stigma Around Lung Cancer - ACCESS Newswire
Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
The Inner Circle acknowledges, Christopher McCormick as a Pinnacle Professional Member Inner Circle of Excellence - Yahoo Finance
Gilead Sees Success With HIV PrEP Trial In South Africa - Clinical Leader
Gilead: Expansion Of Livdelzi For PBC Continues With European Marketing Approval - Seeking Alpha
Gilead Sciences Inc (GILD) Shares Up 1.14% on Mar 22 - GuruFocus.com
Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences Inc (GILD) - GuruFocus.com
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed - Benzinga
Gilead Sciences Inc (GILD) Stock Price Up 0.52% on Mar 21 - GuruFocus.com
Gilead Sciences stock performance analysis: A rare Nasdaq gem with consistent returns across time horizons - The Financial Express
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics - Yahoo Finance
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
GILD Stock Down on Report of Cut in HIV Prevention Spending - Yahoo Finance
Oppenheimer doesn’t see threat to Gilead estimates after HHS plans for HIV cuts - Yahoo Finance
Gilead Stock Wobbles On Federal HIV Funding Cut Buzz, But Retail And Analysts Stay Unfazed - MSN
Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides - Yahoo Finance
Gilead Stock Falls on Report U.S. Could Slash HIV-Prevention Budget - The Wall Street Journal
Gilead stock falls on report of HIV prevention cuts - Yahoo Finance
Gilead Stock Dives On A Devastating Potential Call From HHS - Investor's Business Daily
Stock of the Day: Gilead Sciences falls on report the Trump administration could slash funds for HIV prevention - Yahoo Finance
Wall Street weighs in on Gilead as shares fall on possible U.S. HIV cuts - Investing.com Canada
BMO reiterates Gilead stock with $115 target amid HIV funding concerns - Investing.com
Citi maintains Gilead stock Buy rating, $125 target amid HIV funding fears - Investing.com
Gilead Sciences Should Not See Any Impact From HIV-Related Cost Reductions at US Healthcare Department, Truist Says - Marketscreener.com
Gilead Sciences Ranked in Top Five Most JUST List for Biopharma Companies - CSRwire.com
Gilead Sciences’ SWOT analysis: HIV giant’s stock faces pivotal transition - Investing.com
Gilead Sciences Stock Slips on Possible HIV Funding Cut - Schaeffers Research
Why Gilead Sciences (GILD) Is Among the Most Undervalued Biotech Stocks to Invest In - Insider Monkey
Citi Defending Gilead Sciences (GILD): 'we are buyers of GILD stock on any weakness ahead of the upcoming Len PrEP launch in mid-2025' - StreetInsider.com
Gilead Stock Falls on Report Trump Administration Wants to Cut HIV-Prevention Funding - Barron's
Gilead Stock (NYSE:GILD) Slumps on HIV Funding Cuts Report - TipRanks
Gilead slides as Trump administration puts HIV prevention funds under review - TradingView
Gilead Sciences (GILD): Potential Impact of Federal HIV Funding Cuts - Value the Markets
Gilead, GSK could be impacted by potential HHS HIV prevention cuts - Seeking Alpha
Gilead Sciences CFO Andrew Dickinson sells $276,325 in stock - Investing.com
After-hours movers: Gilead Sciences, HealthEquity, CARGO Therapeutics and more - Investing.com
Gilead Sciences stock falls on potential HIV funding cuts By Investing.com - Investing.com Australia
Gilead Sciences stock falls on potential HIV funding cuts - Investing.com
Unpacking the Latest Options Trading Trends in Gilead Sciences - Benzinga
Gilead Sciences (GILD): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance
Coronavirus: La Commission européenne signe un accord avec Gilead sur le remdesivir - Reuters
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.71%
0.27%
자본화:
|
볼륨(24시간):